ON
← Back to feed
United StatesHealth5 days ago

CMS proposes codifying, strengthening Medicare drug price negotiations

The Centers for Medicare and Medicaid Services (CMS) has proposed changes to the Medicare Drug Price Negotiation Program, aiming to codify the program's requirements and close a potential loophole that drugmakers might exploit. Established under the Inflation Reduction Act, the current program operates via guidance documents rather than binding federal rules. If approved, the new rules would formalize the selection process for drugs eligible for negotiation and impose stricter requirements on manufacturers. The proposal also addresses a potential loophole where drugmakers could alter non-core 

Health Care

PRESENTED BY

The Big Story

CMS proposes codifying, strengthening Medicare drug price negotiations

The Centers for Medicare and Medicaid Services (CMS) is proposing changes to the Medicare Drug Price Negotiation Program that would codify  the requirements of the program and close a potential loophole that drugmakers could exploit.

© Jenny Kane, The Associated Press

Established by the Inflation Reduction Act (IRA), the Medicare Drug Price Negotiation Program is currently carried out through  guidance documents . Unlike a federal rule, guidance is nonbinding and open to interpretation. Codifying these requirements would essentially make it harder to challenge the program.

If approved, these codified rules would direct negotiations beginning in  2029 .

CMS’s proposal would codify the process through which drugs are selected for Medicare negotiation as well as the requirements placed on the manufacturers of the chosen medications.

The proposal also makes note of a potential loophole that drugmakers could take advantage to  escape Medicare negotiation . Drugmakers could theoretically change one ingredient in their product, separate from the active pharmaceutical ingredient, or change how it’s administered and market it as something new to make it ineligible for negotiation.

To address this potential loophole, CMS is proposing that two different products with the same active ingredient can be equally considered for Medicare negotiation if the license holder is the owner of both products and the new formulation is just meant to create a new route of administration.

The 60-day comment period on the rule will close on Aug. 17, 2026.

Welcome to The Hill’s Health Care newsletter , we’re Nathaniel Weixel and Joseph Choi — every week we follow the latest moves on how Washington impacts your health.

The Hill Insider is coming

A new all-access digital subscription from The Hill — launching July 2026. Join the waitlist to be among the first inside

Essential Reads

How policy will be impacting the health care sector this week and beyond:

Millions of dollars’ worth of contraceptives meant to be distributed to low-income nations in Africa have expired, but the Trump administration is paying tens of thousands of dollars a month to keep them in storage in Belgium, according to a report from the U.S. Agency for International Development’s (USAID) inspector general.  About $9.7 million worth of taxpayer-funded contraceptives purchased by USAID …

Health and Human Services Secretary Robert F. Kennedy Jr. is demanding answers from a science journal on why a study regarding vaccination and sudden infant death was removed from the publication. In a letter dated June 11, Kennedy wrote to Toxicology Reports Editor-in-Chief Lawrence H. Lash concerning a 2021 study titled “Vaccines and sudden infant death: An analysis of the VAERS database 1990–2019 and review of the …

The Food and Drug Administration (FDA) this week approved the first new sunscreen filter in more than two decades, sparking industry-wide excitement. And while this ingredient will be new to the U.S., it’s far from new to the market internationally.  The FDA broke a 27-year dry spell on Tuesday when it added bemotrizinol, sold under the brand name PARSOL® Shield, to its list of permitted sunscreen active ingredients. In …

On Our Radar

Upcoming news themes and events we’re watching:

The Senate Health, Education, Labor, and Pensions Committee is scheduled to hold an executive session to go over legislation on Wednesday.

CONTENT FROM OUR SPONSOR

Invested in Responsibility

Our approach to helping prevent underage access to nicotine products: Responsible marketing. Responsible retail safeguards. Real-world monitoring.

In Other News

Branch out with a different read from The Hill:

Vice President Vance is taking center stage as the U.S. is poised to sign a preliminary deal with Iran to reopen the Strait of Hormuz, in what could prove to be a political opportunity or minefield as he seeks to tout his credentials ahead of 2028.

Around the Nation

Local and state headlines on health care:

NY essential plan: What to do if you lose health care on July 1 ( New York Focus )

State names first round of projects funded by federal rural health program ( Nevada Current )

In  Alabama , these patients have to take monthly pregnancy tests for medical cannabis ( AL.com )

What We’re Reading

Health news we’ve flagged from other outlets:

RFK Jr.’s olive branch  isn’t winning over his staffers ( Politico )

They’re uninsured after  Obamacare became too costly . And they’re far from alone. ( KFF Health News )

Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end ( Stat )

You’re all caught up. See you tomorrow!

Close

The latest in politics and policy.

Direct to your inbox.

Sign up for the Health Care newsletter

Tags

Centers for Medicare & Medicaid Services

CMS

medicare

Medicare Drug Price Negotiat…

Read the full article at The Hill
Source document: Centers for Medicare and Medicaid Services (CMS)

1 reports

The HillIndependentCenter5 days ago
CMS proposes codifying, strengthening Medicare drug price negotiations

The Centers for Medicare and Medicaid Services (CMS) has proposed changes to the Medicare Drug Price Negotiation Program, aiming to codify the program's requirements and close a potential loophole that drugmakers might exploit. Established under the Inflation Reduction Act, the current program operates via guidance documents rather than binding federal rules. If approved, the new rules would formalize the selection process for drugs eligible for negotiation and impose stricter requirements on manufacturers. The proposal also addresses a potential loophole where drugmakers could alter non-core 

Bias read (Center): The article presents factual information about CMS proposals without overtly favoring any political side. It explains the technical aspects of the Medicare Drug Price Negotiation Program and mentions both the potential challenges and solutions related to drug pricing, maintaining a balanced tone.

Official sources cited

Go to the primary sources (1)

The official sources this coverage is built on. Read them directly to bypass framing.